EHA2024 Hybrid Congress

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

EHA-SWG Transfusion Teaser Meeting

On March 29 the 'teaser' meeting “Transfusion medicine: a short journey around Europe” in which key opinion leaders  discussed shaping the EHA-SWG roadmap in the next 5-10 years took place virtually.

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

EHA-ASH Translational Research Training in Hematology

TRTH 2025 call is now closed. What is Translational Research Training in Hematology?

Translational Research Training in Hematology (TRTH) provides early-career researchers with a unique, year-long training and mentoring experience.

The glamorous life of parenthood and medicine

The glamorous life of parenthood and medicine

By Ana Zelić Kerep, MD (YoungEHA Ambassador)

Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…

Current status of the Clinical Trials Regulation

HemAffairs Article #2 – June 2019

In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.